Update on Shingrix supply for Q4 2018 and 2019
, providers should anticipate for Shingrix through 2019 because of high levels of demand.
GlaxoSmithKline (GSK), which makes Shingrix (zoster vaccine recombinant, adjuvanted), increased the U.S. supply available for 2018 and plans to make more doses available in the United States in 2019. In addition, the manufacturer will continue to release doses to all customer types on a consistent and predictable schedule during 2019.
From launch to the end of Q3 2018, nearly 7 million doses of Shingrix have been administered globally—most of which were administered in the United States, according to information from GSK. GSK also has been shipping product every 2–3 weeks to help establish predictability of supply and inform customer planning. Wholesalers and distributors can expect shipments on this schedule for the rest of 2018.
Shingrix is a vaccine indicated for the prevention of herpes zoster (shingles) in adults aged 50 years and older. It is not indicated for prevention of primary varicella infection (chickenpox).
Two doses (0.5 mL each) are administered intramuscularly according to the following schedule: a first dose at month 0 followed by a second dose administered any time between 2 and 6 months later.
According to CDC, Shingrix is the preferred shingles vaccine. CDC’s clinical guidance during the Shingrix delay includes making every effort to ensure that the two doses are administered within the recommended interval. If more than 6 months have elapsed since the first dose, administer the second dose as soon as possible. Do not restart the vaccine series, and do not substitute Zostavax (zoster vaccine live) for the second dose of Shingrix. If the provider is out of Shingrix and a patient needs a second dose, the Vaccine Finder can help the patient locate other providers that have Shingrix.